Aiming for precision: CYP2C19 gene polymorphism and clopidogrel resistance in patients with peripheral artery disease

Antiplatelet therapy with aspirin and/or one of the P2Y12 inhibitors (e.g., clopidogrel, prasugrel, and ticagrelor) is the cornerstone of medical therapy to mitigate the risk of ischemic events in patients with atherosclerotic cardiovascular diseases (ASCVD) [1]. Moreover, dual antiplatelet therapy (DAPT) is the standard of care following percutaneous revascularization of coronary, lower extremity and carotid arteries [2 –4]. Clopidogrel is the most widely used P2Y12 inhibitor but requires hepatic activation by the cytochrome P450 (CYP) 2C19 enzyme [5].
Source: Thrombosis Research - Category: Hematology Authors: Source Type: research